MedCity News January 12, 2026
AbbVie is now part of a growing group of companies that have turned to China to get a bispecific antibody designed to target PD-1 and VEGF to fight cancer. AbbVie may have more to say about the deal in its presentation this week during the annual J.P. Morgan Healthcare Conference in San Francisco.
AbbVie is diversifying its oncology pipeline, paying $650 million for a clinical-stage drug that goes after two targets to fight cancer. It’s the latest in a series of industry transactions for assets in this emerging drug class, and like the others, AbbVie’s new large molecule comes from China.
The drug, RC148, was developed by Yantai, China-based RemeGen. The deal terms announced Monday give AbbVie global rights to...
Today's Sponsors
Today's Sponsor